Matuzumab
Based on 1 Customer Validation
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.50%
- CAS 番号: 339186-68-4
- 分子量:145.5 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB1/EGFR/HER1
体外実験
Matuzumab (10 ng, 4-72 h) can exert a powerful anti-tumor ADCC effect in the target monolayer cells of head and neck squamous cell carcinoma (SCCHN)[2].
Matuzumab was enzymatically de-glycosylated to eliminate its ADCC activity, but the de-glycosylated antibody maintained its ability to bind to A431 tumor cells, block EGFR signaling, and inhibit growth in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:UM-SCC 14C, UDSCC 4, MCF-7, UM-SCC 11B and 22B
-
Concentration:10 ng
-
Incubation Time:4, 24 or 72 h
-
Result:The increase of effector:target ratios caused enhanced tumour cell killing.
Led to a significant enhancement of effector cell activity and increased ADCC.
体内実験
Matuzumab achieves complete remission in 87% of lung cancer xenografts and 83% of gastric cancer xenografts. The growth of drug-resistant pancreatic cancer xenograft tumors decreases by 31%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 nd
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human EGFR Protein (ECD, His Tag) can bind Matuzumab. The EC50 for this effect is 1.802 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Matuzumab (anti-ERBB1/EGFR/HER1) (HY-P9969). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 339186-68-4
-
性状 Liquid
-
分子量 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Matuzumab]
-
別名
EMD 72000
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Joan H Schiller. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). Cancer Invest. 2008 Feb;26(1):81-95. [Content Brief]
[2]. Bier H, et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 1998 May;46(3):167-73. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)